Moonwalk Biosciences, a biotechnology firm at the forefront of epigenetic and RNA interference (RNAi) research, has successfully closed an oversubscribed $70 million Series B financing round. The capital injection is earmarked for the development of a new class of medicines that target adipose tissue directly, offering a specialized alternative to the current landscape of incretin-based weight loss treatments. This funding marks a pivotal moment for the company as it prepares to transition from a discovery-phase entity into a clinical-stage organization, with its lead candidate, MW101, projected to enter human trials by late 2027.
The financing round was co-led by Alpha Wave Global and YK Bioventures. It drew significant attention from industry heavyweights, including Eli Lilly and Company—a dominant player in the metabolic health space—as well as Gaorong Ventures. Participation also included existing backers ARCH Venture Partners, Khosla Ventures, and Future Ventures. The diversity of the investor group reflects a growing appetite for "non-incretin" pathways in the treatment of obesity, which currently accounts for billions of dollars in global healthcare spending.
A New Frontier in Obesity Treatment: Adipose-Targeted RNAi
For several years, the obesity treatment market has been dominated by GLP-1 (glucagon-like peptide-1) receptor agonists, which primarily function by regulating appetite and slowing gastric emptying through the brain-gut axis. While highly effective, these treatments often require weekly injections and can lead to significant loss of lean muscle mass alongside fat reduction. Moonwalk Biosciences is pursuing a fundamentally different biological route.
Moonwalk’s proprietary platform utilizes small interfering RNA (siRNA) designed to be delivered specifically to adipose (fat) tissue. By modulating the genetics and epigenetics of fat cells themselves, the company aims to influence energy homeostasis, adipogenesis (the formation of fat cells), lipolysis (the breakdown of fats), and thermogenesis (heat production). This tissue-specific approach is intended to minimize systemic side effects while maximizing the impact on the metabolic health of the patient.
The core of Moonwalk’s technology relies on an exclusive licensing agreement for adipose-targeting chemistry from Suzhou Siran Biotechnology Co., Ltd. This chemistry acts as a delivery vehicle, ensuring the siRNA reaches the fat cells without being degraded or diverted to other organs like the liver, which is the traditional destination for most siRNA therapies currently on the market.
Preclinical Performance and Clinical Timeline
The Series B proceeds will primarily fund the advancement of MW101, the company’s lead obesity candidate. In preclinical models, including studies involving non-human primates, Moonwalk’s therapies have demonstrated the ability to produce robust reductions in total body weight and fat mass. Crucially, these results were achieved while preserving lean muscle mass, addressing one of the primary criticisms of current-generation weight loss drugs.
Furthermore, the preclinical data suggests a durable effect. Following a single dose in primate studies, target engagement in adipose tissue remained high for extended periods. This indicates that Moonwalk’s therapies could potentially be administered as infrequently as once every three or six months, a significant improvement over the weekly dosing schedules required by many existing treatments.
The company is currently engaged in IND-enabling (Investigational New Drug) studies. If these remain on track, the first-in-human clinical studies are expected to commence in the latter half of 2027. Beyond MW101, the company is leveraging its AI-enabled discovery platform to build a pipeline of other tissue-targeted siRNA medicines for various cardiometabolic conditions, including NASH (non-alcoholic steatohepatitis) and type 2 diabetes.
Strategic Leadership and Market Positioning
As Moonwalk prepares for its clinical phase, it has bolstered its leadership team with the appointment of Dr. Stephen Djedjos as Senior Vice President of Clinical Development. Dr. Djedjos brings two decades of experience in drug development, most recently serving as a leader at Kailera Therapeutics, where he focused on incretin therapies. His background as a pediatric endocrinologist and his previous roles at Amgen and Gilead Sciences provide the clinical depth necessary to navigate the complex regulatory environment of metabolic medicine.
"Obesity places an extraordinary physical and emotional burden on millions of people," stated Alex Aravanis, MD, PhD, CEO and co-founder of Moonwalk Biosciences. He emphasized that the direct targeting of adipose tissue represents a "fundamentally different approach" that could redefine the standard of care.
The involvement of Eli Lilly in this financing round is particularly noteworthy. As the manufacturer of Zepbound and Mounjaro, Lilly’s investment in a non-incretin, adipose-targeted competitor suggests a strategic interest in diversifying the obesity treatment portfolio beyond appetite suppression. This reflects a broader industry trend toward "precision metabolism," where treatments are tailored to specific cellular dysfunctions rather than broad hormonal pathways.
Medically Modern: Addressing the Administrative Crisis in Endocrinology
While Moonwalk Biosciences focuses on future therapies, Medically Modern is addressing the immediate logistical and administrative challenges facing endocrinology practices today. On September 8, the national durable medical equipment (DME) supplier announced a strategic partnership with a large, multi-location endocrinology practice in Northern Virginia, which serves over 10,000 patients with diabetes.
The partnership is designed to tackle the "administrative burden" that has become a leading cause of burnout among specialized healthcare providers. As the use of Continuous Glucose Monitors (CGMs) and insulin pumps has skyrocketed, so too has the volume of paperwork required for insurance verification, prior authorizations, and medical necessity documentation.
Streamlining the DME Supply Chain
Medically Modern’s model involves taking over the end-to-end management of referrals for diabetic supplies. When a physician prescribes a CGM or an insulin pump, Medically Modern handles the insurance routing—determining whether the device should be processed under the patient’s pharmacy benefit or their DME benefit. This distinction is often a source of significant delay and confusion for both patients and clinical staff.
The partnership provides the care team with real-time visibility into the status of every patient. Through a configured technology platform, the practice can see:
- Whether documentation for medical necessity has been completed.
- The status of insurance verification.
- When the patient receives their first shipment.
- Ongoing resupply schedules.
One of the most critical aspects of this partnership is the "six-month visit" tracking. Most insurance payers require patients to have an in-person or telehealth visit with their endocrinologist every six months to maintain coverage for CGMs and pumps. If a patient misses this window, their supply chain is often cut off, leading to gaps in care. Medically Modern’s system flags patients approaching this deadline, allowing the practice to schedule appointments before a disruption occurs.
Impact on Clinical Outcomes and Practice Efficiency
By automating the "headache" of supply management, Medically Modern aims to return time to providers. Corey Deutsch, founder and CEO of Medically Modern, noted that the strategy was born out of hearing providers repeatedly state they were "drowning in paperwork."
The partnership operates under strict compliance with HIPAA, the federal Anti-Kickback Statute, and the Stark Law, ensuring that the relationship between the DME supplier and the medical practice remains focused solely on patient access and administrative efficiency. Importantly, the clinical decision-making remains entirely with the treating physician; Medically Modern does not influence referral volume but rather optimizes the fulfillment of those referrals.
The Broader Context: The Future of Endocrine Care
The simultaneous developments at Moonwalk Biosciences and Medically Modern highlight a dual-track evolution in the field of endocrinology. On one hand, there is a massive push for scientific innovation—moving away from broad-spectrum hormones toward precise, tissue-targeted genetic modulation. On the other hand, there is an equally urgent need for operational innovation—leveraging technology to manage the increasingly complex logistics of modern diabetes care.
The global obesity market is projected to reach over $100 billion by 2030. However, the success of this market depends not just on the efficacy of the drugs, but on the infrastructure of the healthcare system to deliver them. If physicians are too overwhelmed by paperwork to manage patient visits, the most advanced RNAi therapies in the world will struggle to reach those who need them.
As Moonwalk Biosciences advances its pipeline toward 2027, the industry will be watching closely to see if adipose-targeted therapies can indeed deliver on the promise of "healthy adipose remodeling" without the side effects of current treatments. Meanwhile, the expansion of partnership models like those offered by Medically Modern suggests that the "medically modern" practice of the future will be defined as much by its digital workflow as by its pharmaceutical arsenal.
